Retatrutide
Clinical data | |
---|---|
Other names | LY-3437943 |
Identifiers | |
| |
CAS Number | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C223H343F3N46O70 |
Molar mass | 4845.444 g·mol−1 |
Retatrutide (LY-3437943) is an experimental drug for
GCGR receptors.[1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.[2][3][4] The drug is a peptide with amino acid sequence YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3.[5]
References
- S2CID 251675508.
- ^ "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight" (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.
- ^ Constantino, Annika Kim (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients". CNBC. Retrieved 3 July 2023.
- S2CID 259260926. Free access subject to registration.
- ^ "Compound Report Card". www.ebi.ac.uk. n.d.